



## **Intercell management board resolves € 150 million capital increase – HSR waiting period for the strategic partnership with Novartis has expired**

**Vienna (Austria), August 30, 2007** – The management board of Intercell AG today resolved, subject to the approval of the supervisory board, to issue 4.8 million new shares of common stock to its strategic partner Novartis at an issue price of € 31.25 per share. The subscription rights of existing shareholders will be excluded. The report on the exclusion of the statutory subscription rights will be published tomorrow in the Wiener Zeitung and on [www.intercell.com](http://www.intercell.com).

Within the scope of a strategic alliance agreement concluded in early July 2007, Novartis has committed to subscribe for the newly issued shares, resulting in an investment of € 150 million into Intercell. One of the conditions to closing the strategic partnership was clearance under U.S. antitrust law. Today's resolution to make the capital increase effective follows the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended (the "HSR Act"), whereby the strategic partnership can proceed under U.S. antitrust law. The waiting period expired in the ordinary course under the HSR Act 30 days after the initial filing. Completion of the capital increase and start of trading of the new shares on the Vienna Stock Exchange is expected for mid/end September 2007.

### **About Intercell AG:**

Intercell AG is a growing biotechnology company which focuses on the design and development of novel vaccines for the prevention and treatment of infectious diseases with substantial unmet medical need. The Company develops antigens and adjuvants which are derived from its proprietary technology platforms, and has in-house GMP manufacturing capability. Based on these technologies, Intercell has strategic partnerships with a number of global pharmaceutical companies, including Novartis, Merck & Co., Inc., Wyeth, sanofi pasteur, Kirin and the Statens Serum Institut.

The Company's leading product, a prophylactic vaccine against Japanese Encephalitis, successfully concluded pivotal Phase III clinical trials in 2006. The regulatory process toward a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) has been initiated. The broad development pipeline includes a Pseudomonas vaccine in Phase II, a therapeutic vaccine for Hepatitis C in Phase II, partnered vaccines for Tuberculosis and Staphylococcus aureus which are in Phase I, and five products focused on infectious diseases in preclinical development. Intercell is listed on the Vienna stock exchange under the symbol "ICLL".

For more information please visit: [www.intercell.com](http://www.intercell.com)



**Contact Intercell AG:**

**Intercell AG**

Mag. Dott. Astrid Meinel

Corporate Communications

Campus Vienna Biocenter 2, A-1030 Vienna

P: +43-1-20620-313 Mail to: [ameinl@intercell.com](mailto:ameinl@intercell.com)

*This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.*

*This document is not for release, publication or distribution in the United States of America.*

*This release does not constitute an offer of securities for sale or a solicitation of an offer to purchase securities in the United States of America, Austria, Germany or any other jurisdiction. The securities of Intercell AG may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. It is not intended to register any securities of Intercell AG in the United States or to conduct a public offering in the United States, Austria, Germany or any other jurisdiction.*